CORRIGENDUM

New Insights for Low Dosing With the New P2Y₁₂ Inhibitors – Lesson From the East –

Johanne Silvain, MD, PhD; Mathieu Kerneis, MD; Jean Philippe Collet, MD, PhD;
Gilles Montalescot, MD, PhD for the ACTION Study Group

(*Circ J* 2014; **78**: 2840–2842)

The authors apologize for the incorrections in the lines 24 to 29, page 2841. The correct spelling is given below.

Incorrect:

In the secondary prevention PEGASUS trial (NCT01225562) trial, a low-dosing strategy is also tested with ticagrelor (60 mg twice daily) in comparison with **clopidogrel**, both in association with aspirin, while the standard dose of ticagrelor (90 mg twice a day) is also tested in a third arm with aspirin **alone**.

Correct:

In the secondary prevention PEGASUS trial (NCT01225562) trial, a low-dosing strategy is also tested with ticagrelor (60 mg twice daily) in comparison with **matching placebo**, both in association with aspirin, while the standard dose of ticagrelor (90 mg twice a day) is also tested in a third arm with aspirin.